Vecabrutinib for Chronic Lymphocytic Leukemia (CLL)
The Leukemia Community - Connect With Other Leukemia Patients
Overview of Leukemias
Newsletter Signup | Join Community | Cancer Types
FDA Approves Venclexta, Daurismo, and Xospata Precision Cancer Medicines for Treatment of Acute Myeloid Leukemia
Brukinsa is a novel BTK inhibitor with encouraging anti-cancer activity in the management of CLL/SLL.
Zanubrutinib, obinutuzumab, venetoclax (BOVen) promising new treatment for Chronic Lymphocytic Leukemia and lymphomas.
Sustained progression free and overall survival benefits with Venclexta combined with Rituxan or Imbruvica.
CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Luskin
FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia
considering CAR T for ALL - anyone been through it yet?
looking for others to share their experience with stem cell transplant for leukemia.